CALGARY, Alberta, Nov. 06, 2025 (GLOBE NEWSWIRE) — TransAlta Corporation (TransAlta or the Company) (TSX: TA) (NYSE: TAC) today reported its financial results for the third quarter ended Sept. 30, 2025. “Our business delivered solid operational performance during the third quarter, demonstrating the Company’s resilience in the face of challenging market conditions. Our Alberta portfolio’s hedging strategy and active asset optimization continued to generate realized prices well above spot prices, while availability remained high across the fleet. Although Alberta power prices remain suppressed, our assets continue to perform well, and we remain confident in achieving results within our 2025 Outlook range,” said John Kousinioris, President and Chief Executive Officer. “We are pleased with the continued progress on a number...

PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated  Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical trials of budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) ongoing, with initial data from both trials expected in H2 2026 Regulatory clearance obtained to initiate CLYM116 Phase 1 trial; anticipate dosing first subject by year-end, with initial data expected mid-2026 Leadership team strengthened with the appointments of Susan Altschuller, Ph.D., MBA, Chief Financial Officer, Adam Villa SVP, Technical Operations, and Ashley Jones SVP, People & Workforce Strategy Cash runway expected through 2027, anticipated to fund company through multiple upcoming clinical milestones WELLESLEY HILLS, Mass., Nov. 06,...

PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarter October 2025 ending cash and cash equivalents of over $100 million; ended Q3 2025 with $85.0 million in cash and cash equivalents after closing of $57.5 million public offering in August 2025, with additional $29.8 million gross proceeds from usage of at-the-market (ATM) offering facility in October 2025 Announced U.S. IND clearance and alignment with U.S. FDA on pivotal clinical program for VYD2311, a vaccine-alternative antibody to prevent COVID REVOLUTION, Invivyd’s development program for VYD2311, comprises the DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials, which are...

NEW YORK, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) — Olaplex Holdings, Inc. (NASDAQ: OLPX) (“OLAPLEX” or the “Company”) today announced financial results for the third quarter ended September 30, 2025. Amanda Baldwin, OLAPLEX’s Chief Executive Officer, commented: “We are pleased with our third quarter results that reflect investments in sales and marketing, continued progress in our executional capabilities and the early results of our latest new product introductions. We are reaffirming our annual guidance and remain focused on our Bonds and Beyond strategy for sustainable, profitable long-term growth.” For the third quarter of 2025 compared to the third quarter of 2024:Net sales decreased 3.8% to $114.6 million;By channel:Specialty Retail decreased 13.5% to $36.9 million; Professional increased...

WEST PALM BEACH, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) — Onity Group Inc. (NYSE: ONIT) (“Onity” or the “Company”) today announced its third quarter 2025 results and provided a business update. Third Quarter 2025:Net income attributable to common stockholders of $18 million; diluted EPS of $2.03; ROE of 14% Adjusted pre-tax income* of $31 million, resulting in annualized adjusted ROE* of 25% Book value per share improved to $62 as of September 30, 2025, up $2.71 YoY Originations volume of $12 billion, up 39% YoY, exceeding industry growth rate Average servicing UPB of $312 billion, up $7 billion YoY2025 Outlook:Expect to exceed 2025 adjusted ROE* guidance range of 16% – 18% Expect to release a significant portion of $180 million deferred tax asset (DTA) valuation allowance as of December 31, 2024, by year-end 2025; third...

BROOKFIELD, NEWS, Nov. 06, 2025 (GLOBE NEWSWIRE) — Brookfield Business Partners (NYSE: BBU, BBUC; TSX: BBU.UN, BBUC) announced today financial results for the quarter ended September 30, 2025. “We made excellent progress in our business over the past few months, completing the acquisition of a Canadian residential and multi-family mortgage lender, generating $180 million from our capital recycling initiatives and announcing the simplification of our corporate structure,” said Anuj Ranjan, CEO of Brookfield Business Partners. “Our plan to convert into a single listed corporation has been well received by our investors and continuing to execute on our strategy should support continued growth in the intrinsic value of our business.”  Three Months EndedSeptember 30,   Nine Months EndedSeptember 30,  US$ millions (except per unit...

Revenue of $674.6 million and Direct-to-Consumer (“DTC”) Revenue of $209.3 millionRevenue Decreased (3.1)% Sequentially and Increased 8.7% Year Over Year DTC Platforms Revenue Increased 19.0% Sequentially and 20.0% Year Over Year HERZLIYA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) —  Playtika Holding Corp. (NASDAQ: PLTK) today released financial results for its third quarter for the period ending September 30, 2025. Financial HighlightsRevenue of $674.6 million decreased (3.1)% sequentially and increased 8.7% year over year. Record DTC platforms revenue of $209.3 million increased 19.0% sequentially and 20.0% year over year. GAAP Net Income of $39.1 million increased 17.8% sequentially and decreased (0.5)% year over year. Adjusted Net Income of $65.8 million increased 912.3% sequentially and 16.3% year over year. Adjusted EBITDA...

Lawrence Fey Appointed Chief Executive Officer Provides 2026 Initial Outlook Driven by Leading Value Proposition & Efficiency Initiatives CHICAGO, Nov. 06, 2025 (GLOBE NEWSWIRE) — Vivid Seats Inc. (NASDAQ: SEAT) (“Vivid Seats” or “we”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today provided financial results for the third quarter ended September 30, 2025 and announced a leadership transition. Third Quarter 2025 Key Operational and Financial MetricsMarketplace GOV of $618.1 million – down 29% from $871.7 million in Q3 2024 Revenues of $136.4 million – down 27% from $186.6 million in Q3 2024 Net loss of $19.7 million – down $28.9 million from net income of $9.2 million in Q3 2024 Adjusted EBITDA...

– Q3 2025 Total Revenue Grew 69% Y/Y to $87.3 Million – – Q3 2025 U.S. Net Product Revenue Grew 31% Y/Y to $40.7 Million – – Reached Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 2040 – – Bempedoic Acid Received Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidemias – – Partner Otsuka Received Regulatory Approval and Favorable Preliminary Pricing to Market NEXLETOL in Japan, Which Will Trigger Significant Milestone Payments Upon Final Pricing Approval – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today reported financial results for the third quarter ended September 30, 2025, and...

SCOTTSDALE, Ariz., Nov. 06, 2025 (GLOBE NEWSWIRE) — LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the third quarter ended September 30, 2025. (All results compared to prior-year comparative period, unless otherwise noted)Q3 2025 Highlights and FY 2025 OutlookRevenue of $363.8 million increased 16% compared to revenue of $312.7 million Clinician base increased 11% to 7,996 clinicians, a sequential net increase of 288 in the third quarter Third quarter visit volumes increased 17% to 2.3 million Net income of $1.1 million compared to net loss of $6.0 million Adjusted EBITDA of $40.2 million increased 31% compared to Adjusted EBITDA of $30.7 million Net cash provided by operations of $27.3 million in the third quarter resulting...